Verubecestat is a small molecule taken orally that targets an enzyme, BACE-1 (beta site amyloid precursor protein cleaving enzyme 1), involved in the creation of amyloid. Since 2000 around 250 ...compounds designed as treatments for Alzheimer's have been tested, and only one has been granted a licence. 1 Kennedy ME Stamford AW Chen X. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients.
Melanoma, prostate cancer, and breast cancer have the highest survival rates, partly accounted for by the high percentage of prostate and breast cancers being detected at an early stage. The ...statistical bulletin is a collaboration between the National Cancer Registration and Analysis Service, which is part of Public Health England, and the Office for National Statistics. “Delivering the prime minister’s commitment will require three things: capital investment for additional diagnostic equipment, such as MRI and CT scanners, significant increases in the cancer workforce to diagnose, treat, and support cancer patients, and help for staff to improve complex services and get the most out of new advances in cancer care.”
Mikael Dolsten, president of worldwide research and development for the company, told a conference in San Francisco on 8 January that Pfizer's focus in the next five years would be oncology, ...inflammation and immunotherapy, vaccines, rare diseases, and pain, where it saw real prospects of creating blockbuster drugs. Picket said that new research at the UK Dementia Research Institute, funded by the Medical Research Council, by his society, and by Alzheimer's Research UK, "aims to reinvigorate the pipeline for drugs that can slow, stop, or prevent this devastating condition."
The team estimated, for example, that in men under 45 with non-HDL cholesterol levels of 3.7-4.8 mmol/L and with at least two risk factors, the long term risk of heart disease could be reduced from ...29% to 6% and in women from 16% to 4%. Long term benefit Colin Baigent, professor of epidemiology at the Clinical Trial Service Unit & Epidemiological Studies Unit at the University of Oxford, who was not a participant in the study, said, “This is an important paper because it shows what could be achieved if, starting early in their 40s, healthy people were to start taking a statin so that their bad cholesterol is halved for the rest of their lives. Paula Byrne is a health services researcher who, as SPHeRE scholar at the National University of Ireland in Galway, recently co-wrote an article in The BMJ on using statins for the primary prevention of cardiovascular disease.2 She commented, “As the modelled risk reduction is based on a 50% lipid reduction, which is likely only be achieved by cholesterol lowering therapy, the side effects of statins and patient preferences for taking lifelong medications would need to be carefully considered.
The real total should be at least 88, said Rod Buchanan, an Australian writer and teacher whose 2010 biography of Eysenck is the most comprehensive study of the controversial figure whose personality ...and ideas dominated British psychology for so long.1 Eysenck’s critics have been calling for decades for the retraction of a series of papers he wrote that used data collected by the German sociologist Ronald Grossarth-Maticek. The King’s College report, compiled by an anonymous group at the college’s Institute of Psychiatry, Psychology and Neuroscience, singled out 26 papers coauthored by the two men, agreeing that the critics were right to throw doubt on them.23 But the report omits many more papers written by Eysenck alone that used the same data, a decision that Buchanan said was “hard to defend.” Buchanan mentions a widely cited 2008 paper on stress related psychosocial factors and cancer incidence and survival that included the data despite its high variance from other studies.5 “Anyone familiar with the scandal surrounding this work would be surprised that it was included in a meta-analysis” was the conclusion of a critical analysis of this paper.6 1 Buchanan R. Playing with fire: the controversial career of Hans J Eysenck.
The outbreak of lung injuries in the US among people using electronic cigarettes should not deter UK smokers from using them, a panel of experts told a briefing at the Science Media Centre in London. ...The US Centres for Disease Control has now given the condition its own name: EVALI, for “e-cigarette or vaping product use-associated lung injury.” “Any given individual may have a lung injury, they may have an infection, or they may have both,” said Ram Koppaka, a medical officer at the CDC’s National Centre for Immunization and Respiratory Disease.
The press spoke with one voice about a recent meta-analysis of statin use in older people, but the figure of 8000 wasn’t in the study. Nigel Hawkes investigates
